Shilpa Medicare has announced its audited consolidated financial results for the quarter and year ended March 31, 2026. The company reported a significant turnaround in its financial performance, with consolidated net profit for Q4 FY26 rising to ₹10,779 lakhs compared to ₹1,451 lakhs in the corresponding quarter of the previous year. Following the earnings announcement, the audio recording of the Q4 FY26 earnings conference call held on May 22, 2026, has been uploaded to the company's website.

Q4 Consolidated Financial Performance

The table below summarizes the key consolidated financial metrics for the fourth quarter:

Revenue from operations for the quarter stood at ₹43,699 lakhs, a substantial increase from ₹33,082 lakhs in the prior year. The company's profit before tax also saw a sharp rise, reaching ₹12,045 lakhs in Q4 FY26 compared to ₹1,527 lakhs in Q4 FY25. Consequently, the net profit for the quarter attributable to owners of the parent company grew to ₹10,779 lakhs.

Annual Performance and Dividend

For the full financial year ended March 31, 2026, the company reported a consolidated net profit of ₹24,333 lakhs, compared to ₹7,829 lakhs in the previous year. Total revenue from operations for the year increased to ₹153,887 lakhs from ₹128,643 lakhs in FY25.

The Board of Directors has recommended a final dividend of ₹0.60 per equity share of face value ₹1 each for the financial year 2025-26. This dividend is subject to approval by the shareholders at the ensuing Annual General Meeting.

Corporate Developments

In addition to the financial results, the Board approved several key corporate actions. The company appointed M/s. V.J. Talati & Co. as Cost Auditors and M/s. Aneja Associates as Internal Auditors for FY 2026-27. Furthermore, the Board approved the shifting of the registered office from Karnataka to Maharashtra, subject to shareholder approval via postal ballot.

The company also announced that its wholly owned subsidiaries will make an equity investment of 28% in Neo Green Power Project Private Limited for captive power consumption. The acquisition is expected to be completed on or before June 15, 2026.

Shilpa Medicare has secured approval from the Central Drugs Standard Control Organisation (CDSCO) for the global Phase 3 plan for its Albumin product, marking a key regulatory milestone in the company's biopharmaceutical development journey.

CDSCO Approval for Global Phase 3 Plan

The CDSCO approval covers the global Phase 3 clinical plan for Albumin, enabling Shilpa Medicare to advance the programme towards international regulatory submissions. This clearance from India's apex drug regulatory authority represents a critical step in the clinical development pathway for the product.

EMA IMPD Submission Targeted in H1 FY27

Following the CDSCO approval, Shilpa Medicare has set its sights on submitting an Investigational Medicinal Product Dossier (IMPD) to the European Medicines Agency (EMA). The company is aiming to complete this submission in the first half of FY27, signalling its intent to pursue regulatory engagement in the European market for the Albumin programme.

Strategic Significance

The dual regulatory development — domestic approval from CDSCO and the planned IMPD submission to EMA — underscores Shilpa Medicare's focus on building a global clinical and regulatory footprint for its Albumin product. The IMPD is a mandatory dossier required by the EMA before initiating clinical trials within the European Union, making its timely submission a pivotal milestone in the product's international development trajectory.